Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

siRNA drug safely halved LDL cholesterol in phase 3 ORION-11

Publish date:: September 4, 2019

Key clinical point: A new drug class safely cut LDL cholesterol with biannual injections in a phase 3 study.

Major finding: Four inclisiran injections administered over 15 months cut baseline LDL cholesterol levels by 50% throughout the study period.

Study details: ORION-11, a multicenter, randomized, phase 3 study with 1,617 patients.

Disclosures: ORION-11 was sponsored by the Medicines Company, which is developing inclisiran. Dr. Ray is a consultant to it and to several other companies.

Citation:

REPORTING FROM THE ESC CONGRESS 2019

This Week's Must Reads

Higher dose maximizes effects of magnesium sulfate for obese women,

Microplastics permeate human placentas,

One in five gestational carriers do not meet ASRM criteria,

Gender surgical outcomes differ following puberty suppression,

COVID-19 vaccine found effective but doctors watching for reactions, adverse events,

Must Reads in Lipid Disorders

Study results support screening rosacea patients for cardiometabolic disease,

Endoscopic intragastric balloon improved NASH parameters,

Obesity phenotyping matches patients with more effective interventions,

Liquid biopsy captures key NASH pathology hallmarks,

GALACTIC-HF: New ‘myotropic’ drug class shows modest HFrEF benefit,